These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26451675)

  • 1. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.
    Deitelzweig S; Evans M; Hillson E; Trocio J; Bruno A; Tan W; Lingohr-Smith M; Singh P; Lin J
    Curr Med Res Opin; 2016; 32(1):87-94. PubMed ID: 26451675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
    An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
    Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
    Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
    Liu S; Li X; Shi Q; Hamilton M; Friend K; Zhao Y; Horblyuk R; Hede S; Shi L
    Curr Med Res Opin; 2018 Mar; 34(3):415-421. PubMed ID: 28945114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States.
    Deitelzweig SB; Evans M; Trocio J; Gupta K; Lingohr-Smith M; Menges B; Lin J
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):364-371. PubMed ID: 28135822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
    Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
    J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.
    Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
    J Med Econ; 2015 May; 18(5):333-40. PubMed ID: 25549062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.
    Mittal VS; Wu B; Song J; Milentijevic D; Ashton V; Mahajan D
    Curr Med Res Opin; 2020 Apr; 36(4):529-536. PubMed ID: 31858841
    [No Abstract]   [Full Text] [Related]  

  • 11. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.
    Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):205-11. PubMed ID: 25944648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
    Mahajan D; Wu B; Song J; Milentijevic D; Ashton V; Mittal VS
    Drugs Aging; 2020 Apr; 37(4):281-289. PubMed ID: 32147804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health care burden of dyspepsia among nonvalvular atrial fibrillation patients.
    Kim MH; Bell KF; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):391-9. PubMed ID: 24684644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.
    Hallinen T; Soini EJ; Asseburg C; Kuosmanen P; Laakkonen A
    BMJ Open; 2014 Feb; 4(2):e004071. PubMed ID: 24578536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
    Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
    Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.
    Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
    Curr Med Res Opin; 2014 Dec; 30(12):2437-42. PubMed ID: 25170587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.